Immunotherapy in the treatment of prostate cancer

03/2019

MUDr. Jana Katolická, Ph.D.

Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno

SUMMARY

Immunotherapy is not used in routine clinical practice in the treatment of prostate cancer. Traditional endpoints used to evaluate chemotherapy may not assess accurately the clinical benefit from immune therapies. The mechanism of action of most immune therapies is not directly cytotoxic. The higher clinical benefit was found in favorable subgroups with a lower tumor burden and a less immunosuppressive tumor microenvironment.

Key words

prostate cancer, imunotherapy